Milestone Achievement in Cardiac Treatment: KingstronBio’s ProStyle M® Valve System Successfully Implanted
On March 12, 2026, a significant milestone was achieved in the field of cardiac treatment with the successful implantation of KingstronBio’s ProStyle M® Transcatheter Mitral Valve System. This procedure took place as part of a national multicenter confirmatory study and was conducted exclusively under ultrasound guidance by esteemed heart surgeons, Professor Wang Chunsheng and Professor Wei Lai, from the Zhongshan Hospital affiliated with Fudan University.
This groundbreaking procedure marks the official commencement of the national multicenter confirmatory clinical study for the ProStyle M® valve system. Previously, the ProStyle M® had undergone a two-year First-in-Man study (FIM) involving 10 patients with an average age of 71 years. The results from this preliminary study were promising, showing excellent anchoring performance with no instances of valve regurgitation observed. As the clinical study progresses, further data will emerge to substantiate the safety and efficacy of the device.
KingstronBio has long been a key player in heart valve innovation, driven by a commitment to research and development. The company claims a robust portfolio of patented technologies, including the Micro-Ex™ technology, which reduces calcification, and the AirBo™ dry storage technology for heart valves. Their mission is to provide safer and more reliable treatment options for patients dealing with moderate to severe mitral insufficiency, a common heart valve disease in China.
Mitral insufficiency (MR) represents the most prevalent heart valve disorder in the country, and the field of transcatheter mitral valve replacement (TMVR) has faced numerous technical challenges over the years. Anatomical complexities, the risk of left ventricular outflow tract obstruction, and difficulties in anchoring and sealing artificial valves have been some of the significant hurdles.
The ProStyle M® valve system is designed to address several of these clinical challenges. By utilizing an eccentric structural design, the procedure's complexity and the risk of left ventricular outflow obstruction are notably reduced while achieving stable anchoring performance and promising hemodynamic outcomes. This innovative structure stands to enhance the overall patient experience during a critical procedure.
Additionally, the ProStyle M® features advanced patented technologies that contribute to its longevity and efficacy. The unique Micro-Ex™ procedure actively reduces calcification by eliminating residual cell debris, phospholipids, and active glutaraldehyde groups present in the pericardium, effectively delaying valve leaflet calcification and improving long-term durability. This, combined with the AirBo™ ventile dry storage technology, ensures enhanced durability and biocompatibility of the valve, supporting patients over extended periods.
KingstronBio remains strongly committed to improving the treatment landscape for structural heart diseases. With an expanded portfolio that includes bioprosthetic heart valves, annuloplasty rings, biopatches for cardiac surgery, and pre-installed dry transcatheter aortic valves, the company aims to fill critical gaps in cardiac care while ensuring that high-quality innovative medical products are accessible to Chinese cardiologists.
The collaboration of experienced professionals and in-depth understanding of cardiac health challenges allows KingstronBio to continue to push boundaries in the medical field. Their research team, led by Beijing Distinguished Experts, holds various international patents related to biomaterials and dry preservation technology.
In conclusion, the successful implantation of the ProStyle M® valve system is just the beginning for KingstronBio. As they continue to secure valuable clinical data, they remain focused on delivering innovations that enhance patient outcomes and redefine the standards of care in cardiac medicine. Their passion for life and commitment to health drive the relentless pursuit of effective medical solutions, demonstrating that through innovation, the challenges in cardiac care can indeed be overcome.
This groundbreaking procedure marks the official commencement of the national multicenter confirmatory clinical study for the ProStyle M® valve system. Previously, the ProStyle M® had undergone a two-year First-in-Man study (FIM) involving 10 patients with an average age of 71 years. The results from this preliminary study were promising, showing excellent anchoring performance with no instances of valve regurgitation observed. As the clinical study progresses, further data will emerge to substantiate the safety and efficacy of the device.
KingstronBio has long been a key player in heart valve innovation, driven by a commitment to research and development. The company claims a robust portfolio of patented technologies, including the Micro-Ex™ technology, which reduces calcification, and the AirBo™ dry storage technology for heart valves. Their mission is to provide safer and more reliable treatment options for patients dealing with moderate to severe mitral insufficiency, a common heart valve disease in China.
Mitral insufficiency (MR) represents the most prevalent heart valve disorder in the country, and the field of transcatheter mitral valve replacement (TMVR) has faced numerous technical challenges over the years. Anatomical complexities, the risk of left ventricular outflow tract obstruction, and difficulties in anchoring and sealing artificial valves have been some of the significant hurdles.
The ProStyle M® valve system is designed to address several of these clinical challenges. By utilizing an eccentric structural design, the procedure's complexity and the risk of left ventricular outflow obstruction are notably reduced while achieving stable anchoring performance and promising hemodynamic outcomes. This innovative structure stands to enhance the overall patient experience during a critical procedure.
Additionally, the ProStyle M® features advanced patented technologies that contribute to its longevity and efficacy. The unique Micro-Ex™ procedure actively reduces calcification by eliminating residual cell debris, phospholipids, and active glutaraldehyde groups present in the pericardium, effectively delaying valve leaflet calcification and improving long-term durability. This, combined with the AirBo™ ventile dry storage technology, ensures enhanced durability and biocompatibility of the valve, supporting patients over extended periods.
KingstronBio remains strongly committed to improving the treatment landscape for structural heart diseases. With an expanded portfolio that includes bioprosthetic heart valves, annuloplasty rings, biopatches for cardiac surgery, and pre-installed dry transcatheter aortic valves, the company aims to fill critical gaps in cardiac care while ensuring that high-quality innovative medical products are accessible to Chinese cardiologists.
The collaboration of experienced professionals and in-depth understanding of cardiac health challenges allows KingstronBio to continue to push boundaries in the medical field. Their research team, led by Beijing Distinguished Experts, holds various international patents related to biomaterials and dry preservation technology.
In conclusion, the successful implantation of the ProStyle M® valve system is just the beginning for KingstronBio. As they continue to secure valuable clinical data, they remain focused on delivering innovations that enhance patient outcomes and redefine the standards of care in cardiac medicine. Their passion for life and commitment to health drive the relentless pursuit of effective medical solutions, demonstrating that through innovation, the challenges in cardiac care can indeed be overcome.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.